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CObjectives: To assess the value for money of alternative chemother-
apy strategies for managing advanced colorectal cancer using irinote-
can or oxaliplatin, either in sequence or in combination with
fluorouracil. Methods: A cost-effectiveness model was developed us-
ing data from the UK fluorouracil, oxaliplatin, and CPT11 (irinotecan) –
use and sequencing (FOCUS) trial. The analysis adopted the perspective
of theUKNational Health Service. Input parameterswere derived using
a system of risk equations (for probabilities), count data regression
models (for resource use), and generalized linear models (for utilities).
Parameter estimates were obtained using Markov chain Monte Carlo
methods, propagating the simulation values through the state-transi-
tion model to characterize appropriately the joint distributions of ex-
pected cost, survival and quality-adjusted life years for each treatment
strategy. An acceptability frontierwas used to represent the probability
that the optimal option is cost-effective at different values of the cost-
effectiveness threshold. Results: The base-case analysis used drug O
onom
al So
oi:10.1016/j.jval.2011.07.008nit costs provided by a typical English hospital. First-line doublet ther-
py combination therapy fluorouracil (5FU) plus irinotecan was the
ost cost-effective strategy at standard thresholds, with an incremen-
al cost-effectiveness ratio (ICER) of £14,877 (pound sterling) compared
ith first-line 5FU until treatment failure followed by single agent iri-
otecan. Other strategies were all subject to extended dominance. A
ensitivity analysis using published drug (list) prices found the most
ost-effective strategy would be first-line fluorouracil until failure fol-
owed by 5FU plus irinotecan (ICER: £19,753). Conclusions: The combi-
ation of 5FU and irinotecan (whether used first or second line) appears
o be more cost-effective than the single agent sequential therapies
sed in the FOCUS trial, or 5FU plus oxaliplatin.
eywords: advanced colorectal cancer, cost-effectiveness, FOCUS trial,
rinotecan, oxaliplatin.
opyright © 2012, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Colorectal cancer is the third most common cancer in the United
Kingdom, with almost 30,000 new cases registered in England and
Wales in 2001, representing over 12% of all new cancer cases [1,2].
“Advanced” colorectal cancer (ACRC) is described as a disease that
is either metastatic or too locally advanced for complete surgical
resection of the primary tumor. Approximately 55% of colorectal
cancer patients in England and Wales have ACRC, either at the
time of initial presentation or later in the disease course [3,4].
A small but increasing proportion of patients with ACRC are
suitable for treatment with curative intent, usually involving ma-
jor liver and/or lung resections and chemotherapy. For the major-
ity of ACRC patients, however, the treatment objectives are non-
curative: to relieve symptoms and improve quality of life, and to
modestly increase survival duration. Following trial results [5],
palliative chemotherapy became the standard of care in ACRC in
patients who were able to tolerate these therapies. Since the mid-
1990s the standard treatment for such patients was fluorouracil
(FU) with folinic acid, administered in a variety of schedules, the
two weekly de Gramont regimen (dG) or a modification of it (MdG)
being themost popular in theUK. Subsequently, twocytotoxic drugs,
* Address correspondence to: Andrea Manca, Centre for Health Ec
E-mail: am126@york.ac.uk.
098-3015/$36.00 – see front matter Copyright © 2012, Internation
ublished by Elsevier Inc.irinotecan (ir) and oxaliplatin (ox), were licensed. These drugs could
be given either after or in combination with FU, and had good evi-
dence of efficacy but with some additional toxicity [6–8]. They in-
curred significant extra cost [9,10], although both have come off pat-
ent recently, which reduces their acquisition costs and potentially
increases their cost-effectiveness. Since 2004, attention has shifted
to newer therapies targeting the epidermal growth factor and vascu-
lar endothelial growth factor pathways.
TheUKfluorouracil, oxaliplatin, and CPT11 (irinotecan) – use and
sequencing (FOCUS) trial was designed to investigate the optimum
combination and sequencing for FU and either irinotecan or oxalip-
latin in the UK population by comparing five alternative treatment
strategies [11]. The published clinical results of this study indicate
that sequential single-agent therapy with FU followed by irinotecan
produces significantly inferior survival to the same twodrugsusedas
a first-line combination “doublet.” In contrast, treatment strategies
involving FU alone followed by a second-line doublet were non-infe-
rior to first-line doublet therapy [11].
In a fixed budget environment such as the UK National Health
Service (NHS), where decision makers are expected to allocate
available resources efficiently across a wide range of uses, it is
essential to assess the extent to which the benefits of a given
ics, University of York, Heslington, YO10 5DD, York, UK.
ciety for Pharmacoeconomics and Outcomes Research (ISPOR).
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23V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 2 2 – 3 1investment strategy areworth paying for. Cost-effectiveness anal-
ysis (CEA) generates the information decision makers need to
carry out this task [12]. Using individual patient-level clinical and
resource use data from the FOCUS trial, we developed an eco-
nomic model [13] to estimate the long term cost-effectiveness of
the five strategies investigated in the FOCUS trial. Reflecting the
trial population in FOCUS, only patients considered fit enough to
undergo chemotherapy are relevant to the analysis and, given that
palliative chemotherapy is now considered standard of care in
such patients, best supportive care was not considered a relevant
comparator.
Methods
Overview
Individual patient data (IPD) on the use and sequencing of the
study and post-study drugs, non-drug health care resource use
as well as patients’ health-related quality of life through the
EuroQol five-dimension (EQ-5D) questionnaire instrument [14],
ere collected prospectively at each follow up visit during the
rial follow-up.
The median follow-up of the survivors in the FOCUS trial was
6.5 months [11]. Because the differences in benefits and costs
etween the alternative strategies are expected to extend beyond
rial follow-up period, a model to estimate the long-term cost-
ffectiveness of the five management strategies investigated in
he FOCUS trial was developed [15].
The model included costs from the NHS perspective [16] ex-
ressed in UK sterling (2009 prices). Health outcomes were as-
essed in terms of quality-adjusted life years (QALYs) based on
ortality and generic health-related quality of life (HRQoL) using
he EQ-5D data from FOCUS. Costs and QALYs were discounted
sing a 3.5% annual discount rate [17].
Treatment strategies
Following the design of FOCUS, five treatment plans involving
three different strategies for combining and sequencing FU, irino-
Fig. 1 – State trtecan, and oxaliplatin were modeled. These are described below:Strategy A: the standard approach of sequential single-agent MdG
regimen using FU until evidence of treatment failure, followed by
single agent irinotecan;
Strategy B-ir: first-line MdG regimen until treatment failure, fol-
lowed by doublet therapy with MdG and irinotecan (IrMdG regi-
men);
Strategy B-ox: first-line MdG regimen until treatment failure, fol-
lowed by doublet therapy with MdG and oxaliplatin (OxMdG regi-
men);
Strategy C-ir: first-line doublet therapy with the IrMdG regimen;
and
Strategy C-ox: first-line doublet therapy with the OxMdG regimen.
After failing doublet therapy, patients in the C-ir andC-ox arms
of the FOCUS trial may have received non-FOCUS chemotherapy
and eventually salvage therapy. This was due to a change in cross-
over policy half way through the conduct of the FOCUS trial [11].
We used salvage tomean any type of chemotherapy initiated after
patients failed their trial chemotherapy. The costs of any non-
FOCUS chemotherapywere included in the analysis. Themanage-
ment of patients after failing first-line therapy are reported in the
main clinical trial publication [11]. All treatment regimens were
detailed in the protocol, with guidance on dose reductions and
delays for toxicity, and criteria to define treatment failure. For
patients fit andwilling to receive further chemotherapy after com-
pleting the trial strategy, salvage chemotherapy options were of-
fered in the protocol.
Model structure
The structure of the model was designed to reflect the treatment
strategies investigated in the FOCUS clinical trial. Briefly, at any
point in time, individuals were assumed to be in one of four mu-
tually exclusive states (Fig. 1). Specifically, individuals could be
either alive and on a given chemotherapy plan (A to C-ox) and
treatment phase (prior to second line, prior to salvage, salvage), or
dead (for treatment strategies A, C-ox, and C-ir, the transition is
from first line FOCUS to post-FOCUS palliative/salvage treatment).
Transitions between these states were modeled over 3 monthly
intervals and were governed by probabilities estimated directly
tion diagram.ansifrom the FOCUS data.
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Therewere threemain categories of input parameter in themodel,
which included transition probabilities (including mortality); ge-
neric health-related quality of life (estimated using EQ-5D data);
and health care resource use (and costs). More details on the esti-
mationmethods used for each of these parameters are reported in
the statistical methods section.
Transition probabilities
Transition probabilities were used to model the proportions of
individuals in the different model states at each cycle in the
model. The appendix in Supplemental Materials at: doi:10.1016/
j.jval.2011.07.008 details each strategy-specific transition matrix,
together with a brief explanation of how each parameter was de-
rived.
The trial dataset provided information on the occurrence of the
events being modeled (i.e., start and end treatment dates, death)
as represented in Figure 1. Tunnel states, within which modeled
“patients” remain for only one cycle, were used to handle time
dependency in the transition matrix [18].
Generic health-related quality-of-life weights
Estimated QALYs were derived by weighting individuals’ esti-
mated survival duration by their health related quality of lifemea-
sured in terms of their responses to the EQ-5D questionnaire. The
latter was completed at baseline, at 6 and 12 weeks and every 12
weeks thereafter during the trial follow-up period. Details of the
methods used to estimate mean EQ-5D values from FOCUS data
and how these weights were assigned to the corresponding health
states in themodel are provided in the statistical methods section
below. In addition, the appendix reports the values of the model
input parameters that govern the predictions of mean EQ-5D val-
ues associated with each treatment phase.
Health care resource use and costs
The key resource use components included in the analysis were
the drug acquisition and administration of the different chemo-
therapy plans; primary care related (general practitioner atten-
dance, general practitioner visit, district nurse visit); hospital re-
lated (inpatient chemotherapy, general/acute inpatient, day case
general/acute, outpatient medical oncology visits, intensive care
unit, and high dependency unit); and palliative treatment costs
(including salvage chemotherapy, palliative radiotherapy and pal-
liative surgery). The main components of the administration
costs, the mean number of primary care visits, nurse and general
practitioner home visits, and hospital attendances for chemother-
apy administration were estimated directly from FOCUS data.
Briefly, the initial assessment before chemotherapy begins in-
cluded abdominal computed tomography scan, chest x-ray, liver
function test (LFT), full blood count (FBC), and urea and electro-
lytes (U&E). The cost for a single-lumen Hickman line was ob-
tained from providers. The disposable pump cost included all dis-
posables and pharmacist time [19]. The monitoring tests between
chemotherapy cycles included LFT, FBC, and U&E. The cost of the
staff nurse was calculated as cost per minute based on the recom-
mended salary scale for 2009. Other fixed costs related to chemo-
therapy administration, such as adjunctive drugs and monitoring
tests, were based on the FOCUS protocol.
The appendix provides details of themethods used to estimate
themodel inputs parameters attached to each of the above health-
care resource use components, together with the values of these
input parameters. The appendix can be found in supplemental
materials at: doi:10.1016/j.jval.2011.07.008.
Unit costs used to quantify the total costs associated with the
use of the above health care resources are deterministic inputs in
the model.In the base-case analysis, study drug unit costs were estimated
using the figures provided by an (unnamed) NHS Trust (personal
communication). This choice was dictated by the need to make
sure our analysis is relevant to decisionmakers in the UK by using
cost figures that are as close as possible to the actual costs faced by
NHS Trusts because some of the study drugs have recently come
off patent and their acquisition cost has decreased significantly. A
sensitivity analysis was conducted on the key drug costs in the
study, with the objective of assessing their impact on the cost-
effectiveness model results. The sensitivity analysis used British
National Formulary (BNF) prices [20] for the study drug costs, and
these figures are reported in brackets under the base-case values.
Item-specific unit costs used in the base case and sensitivity anal-
yses are reported in Table 1.
Drug acquisition costs were calculated using the most eco-
nomic vial size and with allowance for wastage, and chemother-
apy cycles are administered as a general medicine day case or
medical oncology outpatient visit as derived from the patient level
data. As an approximation of the cost of palliative care for ad-
vanced colorectal patients in the terminal phase, all patients who
reached the salvage stage were assumed to incur a cost of 2 weeks
as hospital at home before death, based on national mean esti-
mates of hospital at home/early discharge schemes [21]. Estimated
resource utilization was combined with unit cost information to
quantify the average cost per patient associatedwith each chemo-
therapy plan. Average salvage chemotherapy costs were based on
the drugs and dosage recommended in the FOCUS protocol. Pri-
mary care and hospital-related costs were estimated based on na-
tional databases [21].
Cost-effectiveness analysis
The FOCUS data were analyzed according to the intention-to-treat
principle, including all randomized patients regardless of their
compliance. The model was run for a period of 10 years, after
which the great majority of patients were expected to have died.
Therefore, the mean life years and QALYs per patient were calcu-
lated for each plan, as well as the mean lifetime costs. The model
reflected the average patient characteristics at randomization in
the FOCUS trial.
The results of themodel are presented in twoways. First,mean
survival, lifetime cost, and QALYs for each strategy are reported
and their cost-effectiveness compared, estimating incremental
cost-effectiveness ratios (ICERs) as appropriate, using standard
decision rules [22]. The interpretation of these ICERs required an
external cost-effectiveness threshold such as the National Insti-
tute of Health and Clinical Excellence’s (NICE) £20,000 to £30,000
per QALY gained [16].
Second, cost-effectiveness acceptability curves (CEACs) are
used to represent the decision uncertainty surrounding adoption
decisions [23]. These curves plot the probability that a given strat-
egy ismore cost-effective than the others for a range of alternative
threshold cost-effectiveness values. Because there are five com-
peting treatment strategies, an additional curve, namely the cost-
effectiveness acceptability frontier (CEAF), is presented here. The
frontier plots the probability that the optimal option is cost-effec-
tive (at different threshold values) [23].
Statistical methods
Input model parameters were estimated from the FOCUS trial in-
dividual patient level data as follows. A series of multinomial re-
gression models was used to analyze the trial data on treatment
failure and treatment switch, with the objective of estimating (im-
plicitly time dependent) probabilities of transition from a given
state (as described in Fig. 1) to another. Health care resource use
associated with each state in the model was estimated from the
FOCUS data using a zero-inflated Poisson model [24] for each re-
eral p
25V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 2 2 – 3 1source use category separately. The use of non-chemotherapy sal-
vage treatments were analyzed using a Bernoulli model of occur-
rence during each Markov cycle.
Finally, the EQ-5D values for specific states in the cost-effec-
tiveness model were estimated using a two-part model [24]. First,
a logitmodelwas used to quantify the probability of a patient being
in full health (e.g., EQ-5D score equal to 1); and second, a scaled
gammamodel, was used to estimate the quality of life decrements
for those individuals in the trial with an EQ-5D score of less than 1.
Predictions from the two-part model were used to estimate mean
EQ-5D scores for each health state in the model together with
Table 1 – Unit costs.
Item of resource use Base case value (B
prices in brackets
Chemotherapy acquisition drugs
5-Fluorouracil (FU) £1.75 (£32)
5-Fluorouracil (FU) £3.50 (£64)
Irinotecan £13 (£53)
Irinotecan £32 (£130)
Oxaliplatin £31 (£165)
Oxaliplatin £61 (£330)
Capecitabine £45
Capecitabine £258 (£295)
Mitomycin C (£30) (£36)
Adjunctive drugs, devices, and
monitoring tests
Heparin sodium £0.25
Normal saline £0.50
Dexamethasone £1.73
L-folinic acid £16 (£85)
Granisetron £0.62 (£26)
Dexamethasone £0.68 (£2)
Dextrose £0.50
Abdominal CT scan £75.21
Chest X-ray £21.20
Full blood count £2.42
Urea and electrolytes £1.12
Liver function test £0.61
Single-lumen Hickman line £64.86
Infusor system £35 (£77)
Primary care and hospital-
related costs
GP attendance £23
General practitioner visit £70
District nurse visit £22
Staff nurse, day ward £0.61
Day case ward £61
Outpatient ward £102
Intensive care unit £1,402
High-dependency unit £607
Inpatient chemotherapy ward £255
Inpatient general/acute ward £252
Terminal patients – home care £299
Non-focus anticancer treatment
MF – PVI FU mitomycin £140
Oxalicap £496
Irinocap £425
Radiotherapy £86
Palliative surgery £735
Note: Price year 2009 using Hospital and Community Health Services
Dosage cost calculations use by default the more appropriate packag
Costs given in pound sterling (£).
BNF, British National Formulary; CT, computed tomography; GP, genrelevant measures of sampling uncertainty.Probabilistic sensitivity analysis
The model was probabilistic in that all input parameters were
assigned probability distributions to reflect their sample vari-
ability, as estimated from the trial data. Estimation of model
input parameters and evaluation of the model outputs were
carried out simultaneously to fully represent the uncertainty in
the results [25]. The output from the Markov chain Monte Carlo
simulation used to estimate the input parameters was used to
propagate parameter uncertainty through themodel, in order to
estimate the joint distribution of costs and effects for each
Unit/dosage Source
25 mg/ml, 100-ml vial NHS Trust and [18]
50 mg/mL, 100-ml vial NHS Trust and [18]
20 mg/ml, 2-ml vial [18]
20 mg/mL, 5-ml vial [18]
50-mg vial NHS Trust and [18]
100-mg vial NHS Trust and [18]
150 mg [18]
500 mg NHS Trust and [18]
20-mg vial NHS Trust [18]
5 ml [18]
250 ml UCLH NHS Trust
2 mg, 20 tablets pack [18]
17.5-ml vial NHS Trust and [18]
3-ml amp NHS Trust and [18]
8 mg/mL NHS Trust [18]
250 ml, 5% UCLH NHS Trust
Item York NHS Trust
Item York NHS Trust
Item York NHS Trust
Item York NHS Trust
Item York NHS Trust
Item Bard
Item NHS Trust and [42]
Per visit [42]
Per home visit [42]
Per home visit [42]
Per min patient contact [42]
Visit [19, 42]
Visit [19, 42]
Day [19, 42]
Day [19, 42]
Day [19, 42]
Day [19, 42]
Day [19, 42]
Per cycle [18]
Per cycle [18]
Per cycle [18]
Per cycle [19, 42]
Per intervention [19, 42]
nd prices index (PSSRU 2010). PSSRU costs all include qualifications.
depending on the number of vials required.
ractitioner; NHS, National Health Services.NF
)
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e sizetreatment strategy [26].
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software package R (Foundation for Statistical Computing, Vi-
enna, Austria) [27], whereas transition probabilities, survival
weights for each health states, costs, and health-related quality
of life were estimated using the freely available Bayesian soft-
ware WinBUGS (Medical Research Council Biostatistics Unit,
Cambridge, England) [28].
Results
A total of 2135 patients were accrued to the FOCUS trial, at 61
centers, between May 2001 and December 2003. Their character-
istics and full details of the treatment received and clinical out-
comes are given in the main clinical report [11].
Mean costs per patient
Figure 2 illustrates the base-case total estimated mean cost per
atient by health care resource use component. Hospital-related
osts were the biggest contributor to the overall expected costs for
ll treatment plans (between 50% and 55% of total costs). In abso-
ute terms, all strategies were very similar; with themain driver of
ost differences among chemotherapy strategies being the acqui-
ition cost of the chemotherapy drugs.
Table 2 reports the base-case estimated mean cost of each
treatment strategy and associated estimated life years and QALYs
over a lifetime time horizon. Strategy C-ir was themost expensive
option, costing an average of £18,034 (95% Credibility Interval [CrI]
£16,546–£19,548) per patient, as opposed to the standard treat-
ment (Plan A), being the cheapest option with an expected cost of
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Fig. 2 – Mean cost per pa£15,965 (95% CrI £15,151–£16,732). This difference is explained bythree factors, as can be seen from Figure 2: the higher acquisition
cost of the chemotherapy drugs, the higher hospital costs, and the
higher cost of the terminal care treatment.
Model validation
Figure 3 depicts the results of the quality assessment of the pre-
dicted versus observed time to death in each of the five treatment
strategies, at each weekly follow-up visit.
It can be seen that the mean squared prediction error (MSPE)
is always less than 0.005, with the exception of week 96 where
the MPSE is 0.01 for one of the strategies. The cumulative MPSE
for each of the treatment strategies over the entire time horizon
ranges between 0.018 (strategy B-ox) and 0.045 (strategy C-ir).
Cost-effectiveness
Consistent with the results of the clinical report [11], strategy C-ir was
found to provide the longest expected mean survival duration of 1.47
years (95% CrI 1.32–1.61), and the highest expected QALYs of 1.07 (95%
CrI 0.97–1.17), whichwas followed by strategies B-ir and B-ox.
Relating QALYs to the cost the NHS has to bear to achieve them
(in the base-case analysis), and using the NICE threshold range of
£20,000 to £30,000 per QALY gained, leads to the conclusion (Table
2) that first-line combination therapy fluorouracil plus irinotecan,
strategy C-ir, is themost cost-effective strategy, among those con-
sidered in the FOCUS trial, with an incremental cost per QALY
gained of £14,877. For threshold values less than £14,877 per QALY
gained, single agent FU followed by single agent irinotecan would
be the most cost-effective option.
Although ICER results can be used to determine the most cost-
B- Bxo - Cri -ir
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presents the study results in the form of a family of CEACs, which
reveals the probability that the different strategies are the most
cost-effective over a range of potential threshold cost-effective-
ness values. At NICE’s £20,000 to £30,000 per QALY gained, the
probability that strategy C-ir is cost-effective ranges between 59%
(at a threshold of £20,000/QALY) and 68% (at a threshold of £30,000/
QALY).
Figure 4B reports the cost-effectiveness acceptability frontier
(CEAF). This curve combines the information from Table 3 and
igure 4A, and plots the probability that the optimal option (the
trategy with the highest average cost-effectiveness) is cost-effec-
ive (at different threshold cost-effectiveness values).
For threshold values less than £14,877 the optimal intervention
s strategy A (as we know from Table 2). The probability of being
he most cost-effective strategy declines as this threshold in-
reases. Because C-ir is, on average,more expensive but generates
ore QALYs than strategy A, it becomes the optimal strategy as
oon as the system is prepared to pay at least £14,877 per QALY
ained.
Table 2 – Estimated mean costs and outcomes per patient
Strategy Mean costs
First-line fluorouracil until
treatment failure, followed by
single agent irinotecan.
(Strategy A)
£15965 (£15151–£16732)
First-line combination therapy
fluorouracil plus oxaliplatin.
(Strategy C-ox)
£17104 (£15877–£18445)
First-line fluorouracil until failure,
then combination therapy
fluorouracil plus oxaliplatin.
(Strategy B-ox)
£17120 (£15958–£18315)
First-line fluorouracil until failure,
then combination therapy
fluorouracil plus irinotecan.
(Strategy B-ir)
£17163 (£15971–£18373)
First-line combination therapy
fluorouracil plus irinotecan.
(Strategy C-ir)
£18034 (£16549–£19502)
Note: Mean and 95% credibility interval (CrI). Discounted at 3.5%. Cos
ICER, incremental cost-effectiveness ratio; LYs, life years; QALYs, qu
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The sensitivity analysis used list prices for pharmaceuticals pub-
lished in the BNF to reflect the possibility that some NHS trusts
could not obtain discounted prices. In the sensitivity analysis pre-
sented here the most significant of these undiscounted prices re-
late to the cost of FU, irinotecan, oxaliplatin, capecitabine, L-Fo-
linic acid, and granisetron.
Under the new set of unit costs, and using the £20,000 to
£30,000 per QALY gained threshold as a reference point, strategy
C-ir was the most expensive option, costing an average of
£23,627 (95% CrI £21,595–£25,676) per patient as opposed to the
standard treatment (plan A), being the cheapest option with an
expected cost of £19,266 (95% CrI £18,239–£20,345).
Under this scenario strategy B-ir is the most cost-effective
strategy, among those considered in the FOCUS trial, with an in-
cremental cost per QALY gained of £19,753. For threshold values of
at least £47,597 per additional QALY, combination therapy C-ir
would be the most cost-effective treatment option. At the other
end of the spectrum, for threshold values less than £19,753 per
-case analysis).
Mean LYs Mean QALYs ICER
.29 (1.2–1.38) 0.93 (0.87–0.99) Cheapest (base for ICER)
.33 (1.2–1.45) 0.95 (0.87–1.04) Extendedly dominated
(by strategy C-ir)
.35 (1.24–1.47) 0.97 (0.89–1.05) Extendedly dominated
(by strategy C-ir)
.36 (1.24–1.48) 1.01 (0.92–1.1) Extendedly dominated
(by strategy C-ir)
.47 (1.32–1.62) 1.07 (0.96–1.18) (To strategy A): £14,877
en in pound sterling (£).
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29V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 2 2 – 3 1QALY gained, single agent FU followed by single agent irinotecan
would be the most cost-effective option. At thresholds of £20,000
to £30,000 per QALY gained, the probability that strategy B-ir is
cost-effective is between 50% and 65%.
Discussion
The objective of the analysis presented here was to estimate the
cost-effectiveness of five treatment plans involving three different
strategies for sequencing FU, irinotecan, and oxaliplatin, for the
treatment of ACRC, reflecting the design of, and using individual
patient level data provided by, the FOCUS clinical trial [11]. FOCUS
compared sequential chemotherapy strategies versus combina-
tion chemotherapy strategies. As such, the latter were first-line
treatments whereas the sequential chemotherapy strategies were
offered as first-line, second line, and salvage depending on the
treatment arm. The structure of the cost-effectiveness model re-
flects accurately the trial design and the alternative treatment
strategies being investigated. To our knowledge this is the first
economic study to use individual patient level trial data to analyze
the cost-effectiveness of planned sequences of chemotherapies
for ACRC from the UK NHS perspective for a patient lifetime hori-
zon.
Relatively few published trials have compared different treat-
ment plans for ACRC in which patients receive the same drugs in
different sequences. Other than FOCUS [11], the Dutch colorectal
cancer group trial [29] and the international LIFE trial [30] both
included evaluation of a strategy of initial single-agent fluoropy-
rimidine, and a French trial [31] compared different sequences of
doublet therapies. Two other trials of initial single versus doublet
therapy have, as yet, been reported only in abstract form [32,33]. In
all these trials only minimal differences in overall survival, not
reaching statistical significance, were observed between the treat-
ment arms [34].
Golfinopoulos et al. [35] recently completed a large network
meta-analysis of randomized trials – comprising 56,677 patients
who were randomly assigned across 580 treatment arms in 242
trials published from1967 to 2007 – comparing systemic treatment
regimens in patients with ACRC. Findings of this meta-analysis
suggest considerable survival benefits in recent years due to the
Table 3 – Main costs and clinical results (sensitivity analys
Strategy Mean costs
First-line fluorouracil until
treatment failure, followed by
single agent irinotecan.
(Strategy A)
£19266 (18239–20345)
First-line fluorouracil until failure,
then combination therapy
fluorouracil plus irinotecan.
(Strategy B-ir)
£20846 (19369–22521)
First-line fluorouracil until failure,
then combination therapy
fluorouracil plus oxaliplatin.
(Strategy B-ox)
£21333 (19813–22943)
First-line combination therapy
fluorouracil plus oxaliplatin.
(Strategy C-ox)
£23101 (21395–24909)
First-line combination therapy
fluorouracil plus irinotecan.
(Strategy C-ir)
£23627 (21595–25676)
Note: Mean and 95% confidence intervals (CI). Discounted at 3.5%. Co
ICER, incremental cost-effectiveness ratio; LYs, life years; QALYs, qu
* The sensitivity analysis uses the British National Formulary drug cintroduction of new chemotherapy and immunotherapy drugs,such as irinotecan, oxaliplatin, bevacizumab, and cetuximab. For a
patientwith an anticipated 1-year survival on 5FUplus leucovorin,
the addition of irinotecan plus bevacizumab prolonged absolute
survival by 8 months, and the addition of oxaliplatin plus bevaci-
zumab, or irinotecan plus oxaliplatin prolonged absolute survival
by 4.7 months. Survival gains were more modest and less defini-
tive with the addition of either irinotecan or oxaliplatin. These
results are consistent with those reported by the FOCUS trial,
which is not surprising since FOCUS was one of the largest trials
included in the study by Golfinopoulos et al. [35]. Ideally, future
research work in this area should attempt to integrate the effec-
tiveness results from this network meta-analysis with relevant
resource use and HRQoL data to determine what is the most cost-
effective treatment option for patients with ACRC in a given juris-
diction.
Following the FOCUS trial, first-line treatment with irinotecan
and 5FU is now superseding oxaliplatin and 5FU as the standard
treatment in the UK and has informed the design of the Medical
ResearchCouncil FOCUS3 (NCT00975897) [36] andFOCUS4 (currently
being planned). Both trials use first-line combination therapy 5FU
plus Irinotecan to be their control arm because this was the most
clinically and cost-effective therapy in FOCUS.
In some countries, though not in the UK, a biological therapy
targeting either vascular endothelial growth factor (VEGF) or en-
dothelial growth factor receptor (EGFR) is now commonly added to
first-line chemotherapy for colorectal cancer. Given the high cost
of targeted therapies, it is therefore necessary to consider whether
the health economic analysis of FOCUS, which did not include
targeted therapy, is of relevance in these health systems. The anti-
VEGF agent bevacizumab has been available for addition to che-
motherapy inmany health systems since 2004 to 2006, although it
has not been adopted universally because of its high cost and
relatively modest clinical benefits [37–40]. Of relevance to the cur-
rent study, there is no clear evidence of interaction between bev-
acizumab and the three cytotoxic agents used in FOCUS, either in
terms of efficacy or toxicity, and what differences have been ob-
served have tended to favor combinations with irinotecan/5FU.
Therefore, although FOCUS did not include bevacizumab, and
clearly does not provide any direct evidence of ICERs of bevaci-
zumab-containing combinations, it seems likely that had bevaci-
ean LYs Mean QALYs ICER
(1.2–1.38) 0.93 (0.87–0.99) Cheapest (base for ICER)
(1.24–1.48) 1.01 (0.92–1.1) (to strategy A): £19,753
(1.24–1.47) 0.97 (0.89–1.05) Dominated (by strategy B-ir)
(1.2–1.45) 0.95 (0.87–1.04) Dominated (by strategy B-ir)
(1.32–1.62) 1.07 (0.96–1.18) (to strategy B-ir): £47,597
iven in pounds sterling (£).
adjusted life years.
eported in brackets in Table 1.is)*.
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30 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 2 2 – 3 1similar use across strategies – would be expected to result in sim-
ilar cost increase in each group leading to similar ICERs to those
reported here. Furthermore, their ranking would have been un-
likely to differ. In contrast, EGFR therapies interact with cytotoxic
chemotherapy in terms of toxicity and there appear to be complex,
and as yet poorly understood, efficacy interactions with specific
cytotoxic regimens. Consequently, the results of phase III trials of
EGFR therapies added to first-line chemotherapy are inconsistent,
and even after exclusion of patients with KRAS-mutated tumors,
several trials have reported no evidence of benefit [41,42]. There-
fore, it is not possible to extrapolate ICER data from FOCUS to
anti-EGFR combination therapy.
In 2008 Hind et al. [43] described a systematic review and a
ost-effectiveness model comparing the use of irinotecan, oxalip-
atin, and raltitrexed for the treatment of advanced colorectal can-
er. Most of the data used in the model came from the published
iterature, and where needed, were supplemented by access to
arly FOCUS trial data. The authors concluded that three active
herapies appear to be most clinically effective and cost-effective.
here are several methodological differences between our analysis
nd that published by Hind et al. [43]. First, our model assesses the
ve treatment strategies in FOCUS in a direct head-to-head compar-
son, whereas the Hind et al. study compared each strategy included
n their model against first-line fluorouracil until treatment failure
ollowed by single-agent irinotecan (i.e., our strategy A). Thus, their
odel’s output, ICER, and subsequent conclusions cannot bedirectly
ompared with ours. Furthermore, unlike the model by Hind et al.,
e explicitly excludedpatientswhocouldbenefit fromdown-staging
urgery, which may have affected our survival predictions. Third,
ind et al. valued chemotherapy drugs use at 2004 list prices,
hereas our model valued them both using 2009 prices and using
ore recent discounted figures. Again, this may limit the compara-
ility of the ICER estimates between the twomodels.
It is important to stress that the systematic literature review of
he existing economic studies in this clinical area conducted by
ind et al. [43] found thatmost studies were “. . .subject to a number
f important weaknesses” (see Hind et al., page 87). The authors
iscuss in detail these weaknesses and we invite the interested
eader to refer to their report. One important recommendation of
heir study was that “. . .the most significant improvement to existing
conomic evaluations of these therapies would be the analysis of overall
urvival, whereby evidence of effectiveness would be drawn from clinical
rials that have evaluated planned sequences of chemotherapies” (see
ind et al., page 89). The authors continue, recommending the
ollection of resource use and utilities data as part of the trial. All
his is exactly what the FOCUS trial was set up to do [44].
The FOCUS trial measured generic health related quality of life
sing the EQ-5D questionnaire. The availability of patient-level
Q-5D data represents an added value of the present analysis.
aution should be exercised with the interpretation of health re-
ated quality of life data reported in different ACRC trials. The
iming of the questionnaire administration in relation to the ad-
inistration of chemotherapy and the time profiles of the toxic
ffects of the different chemotherapy regimens may limit compa-
ability between studies. The problemof non-randomcensoring in
he context of ACRC trials, and its effect on health related quality
f life estimates, has been already reported [45]. No method of
ultiple imputations for missing data, however, was used in our
odel because the overall compliancewas very similar among the
ve treatment arms.
Our analysis did not formally quantify structural model uncer-
ainty [46]. This is increasingly being recognized as an important
eature of any decision model, especially when modeling tech-
iques are used to extrapolate the trial data beyond the trial fol-
ow-up period. In the FOCUS trial, 86% of the patients had died by
he end of the follow-up, thus any methodological uncertainty
urrounding our extrapolation results would only affect the re-aining 14% of the sample who were alive at the end of the trial
eriod. Running the model with a shorter time horizon (e.g., 5
ears) did not affect the results of the cost-effectiveness analysis
detailed results not reported). Another element of our model that
ould be subject to model uncertainty analysis concerns the
hoice of the regression models used to analyze the FOCUS trial
ata to derive the various input model parameters. In our study,
hesemodels were chosen based on a visual inspection of the data
nd of fitted residuals, rather than using formal model selection
riteria. Finally, another structural assumption relates to the al-
ernative definitions of the health states, so that in exploring
tructural uncertainty in the model one might want to assess
hether or not structuring themodel around health states such as
rogression-free, post-progression, and death provides a better
epresentation of the data at hand. Future methodological work
ill explore the impact of such a structural model uncertainty on
ur results.
The main conclusion of the present study is that, at conven-
ional levels of cost-effectiveness considered by NICE (£20,000 to
30,000 per QALY gained), first-line combination therapy 5FU plus
rinotecan (strategy C-ir) is the most cost-effective strategy, with
n estimated ICER of £14,877 per QALY gained. The other therapies
nvestigated in FOCUS were dominated. These results are sensi-
ive to the choice of unit costs for the study drugs.
Source of financial support: Principal trial funding was from
he UK Medical Research Council (grant number E164/3). Addi-
ional support in the form of discounted products was provided by
anofi -Synthelabo, Rhone-Poulenc-Rorer (later Aventis), Wyeth-
ederle, and Baxter. These companies did not have access to data,
nd were not involved in trial design, data collection, the decision
o publish, or the writing of the article.
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